Pyxa Pharmaceuticals
PrivateCompany Overview
Pyxa Pharmaceuticals is a biopharmaceutical company that develops CDK2-selective small molecule inhibitors for the treatment of metastatic breast cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
oncologybiopharmaceuticalsmall molecule inhibitorbreast cancer therapyCDK2 inhibitorcancer drugdrug developmenttargeted therapykinase inhibitorpharma biotechclinical trialsprecision medicineNMPAdrug pipelinebiotech startup
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pyxa Pharmaceuticals Comparables
Compare Pyxa Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Incyclix Bio | 84% | |
| Avenzo Therapeutics | 80% | |
| Servier | 76% | |
Pyxa Pharmaceuticals Funding Rounds
Historical fundraising activity
Pyxa Pharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Pyxa Pharmaceuticals's valuation, stock price, and market status.